Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
Hematol., Transfus. Cell Ther. (Impr.)
;
43(2): 191-200, Apr.-June 2021. tab, ilus
Article
in English
| LILACS
| ID: biblio-1286684
ABSTRACT
ABSTRACT This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and from the perspective of hematology consultation.In the first medical appointment, the CV risk factors should be identified to perform the baseline risk stratification, based on the Brazilian Guideline of Dyslipidemia and Atherosclerosis Prevention Update (risk levels very high, high, intermediate and low).Once stratified, the treatment of the CV risk factors should be administered. If the patient presents risk factors, such as hypertension, diabetes, renal disease, smoking and hypercholesterolemia, the evaluation and initial treatment may be done by the hematologist, being an option the request for evaluation by a specialist. If the patient has a history of previous CV disease, we recommend referral to a specialist. As the CV risk score is dynamic and the control of risk factors can reduce the patient risk, this expert consensus recommends that the re-evaluation of the CV risk after the baseline should be performed at 3 months, 6 months and 12 months. After this period, it should be done annually and, for specific patients, at the clinician's discretion.The evaluation of the baseline CV risk and the safe administration of a TKI allow the patient to benefit from the maximum treatment, avoiding unwanted effects.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Protein-Tyrosine Kinases
/
Cardiovascular Diseases
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Heart Disease Risk Factors
Type of study:
Etiology study
/
Practice guideline
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Hematol., Transfus. Cell Ther. (Impr.)
Journal subject:
Hematologia
/
TransfusÆo de Sangue
Year:
2021
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Centro Paulista de OncologiaGrupo Oncoclínicas do Brasil/BR
/
HEMORIO/BR
/
Hospital Santa Marcelina/BR
/
Instituto do Câncer do Estado de São Paulo/BR
/
Pontifícia Universidade Católica de Campinas/BR
/
Universidade Federal de Ciências da Saúde de Porto Alegre/BR
/
Universidade Federal do Paraná - UFPR/BR
/
Universidade de São Paulo - USP/BR
Similar
MEDLINE
...
LILACS
LIS